转移性激素敏感性前列腺癌中3个月和7个月前列腺特异性抗原水平作为总生存预后标志物:SWOG S1216雄激素剥夺联合奥特罗奈或比卡鲁胺3期随机试验结果
基于SWOG S1216 3期随机试验,评估转移性激素敏感性前列腺癌患者接受雄激素剥夺联合比卡鲁胺或奥特罗奈治疗后3个月和7个月PSA水平与总生存的关联。7个月PSA完全缓解(≤0.2 ng/ml)较无缓解(>4 ng/ml)与总生存改善相关(HR 0.20,p<0.0001),3个月完全缓解类似(HR 0.34,p<0.0001),且关联不受治疗臂影响。
要点
- 7个月PSA完全缓解(≤0.2 ng/ml)较无缓解(>4 ng/ml)与总生存改善相关(HR 0.20,p<0.0001)。
- 3个月PSA完全缓解较无缓解与总生存改善相关(HR 0.34,p<0.0001)。
- PSA缓解与生存的关联在两个时间点均不因治疗臂而异。
核心结论
- 3个月和7个月PSA缓解与总生存强烈相关;结合其他新兴预后生物标志物,这些标志物可能有助于早期识别死亡风险最高的患者、辅助临床咨询并设计针对这些患者的未来临床试验。
研究设计与样本
- SWOG S1216 3期随机试验,转移性激素敏感性前列腺癌患者接受雄激素剥夺联合比卡鲁胺或奥特罗奈治疗。
- 3个月PSA可评估1251例,7个月PSA可评估1231例。
- PSA缓解分类:完全缓解为PSA≤0.2 ng/ml,部分缓解为PSA>0.2且≤4 ng/ml,无缓解为PSA>4 ng/ml。
- 采用Cox分析(校正治疗臂及体力状态、疾病严重程度、早期与晚期诱导三个分层因素)评估与总生存的关联;7个月PSA关联为预设目标,3个月PSA关联亦予评估。
主要发现
- 7个月PSA完全缓解较无缓解与总生存改善相关(HR 0.20,p<0.0001)。
- 3个月PSA完全缓解较无缓解与总生存改善相关(HR 0.34,p<0.0001)。
- PSA缓解与生存的关联在两个时间点均不因治疗臂而异。
临床怎么用
- 原文结论指出,3个月和7个月PSA缓解与总生存强烈相关,结合其他新兴预后生物标志物,可能有助于早期识别死亡风险最高的患者、辅助临床咨询并设计未来临床试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A robust decrease in prostate-specific antigen (PSA) in response to androgen deprivation therapy (ADT) has been evaluated as a prognostic factor in patients with metastatic hormone-sensitive prostate cancer (mHSPC) since 2006, but the treatment of mHSPC has since evolved to include intensified therapy. OBJECTIVE: We assessed the association of PSA levels at 3 (PSA-3mo) and 7 (PSA-7mo) mo with overall survival (OS) in patients with mHSPC treated with ADT combined with either bicalutamide or orteronel in the S1216 phase 3 clinical trial. DESIGN, SETTING, AND PARTICIPANTS: PSA responses to treatment of patients in the S1216 trial were categorized as: complete response (CR) if PSA was ≤0.2 ng/ml, partial response if PSA was >0.2 and ≤4 ng/ml, and no response (NR) if PSA was >4 ng/ml. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A Cox analysis (adjusted for treatment arm and three stratification factors: performance status, severity of disease, and early vs late induction) was used for OS association. While PSA-7mo association was a prespecified objective, PSA-3mo association was also evaluated. RESULTS AND LIMITATIONS: A total of 1251 and 1231 patients from the S1216 study were evaluable for PSA-3mo and PSA-7mo, respectively. A PSA-7mo CR was associated with improved OS compared with NR (HR: 0.20; p < 0.0001). A PSA-3mo CR showed a similar association to NR (HR: 0.34; p < 0.0001). The association of a PSA response with survival did not differ by treatment arm at either time point. CONCLUSIONS: The PSA-3mo and PSA-7mo responses were strongly associated with OS; taken with other emerging prognostic biomarkers, these markers may allow for early identification of patients at the highest risk of death, aid with counseling in clinical practice, and permit design of future clinical trials targeting these patients. PATIENT SUMMARY: A low prostate-specific antigen level at 3 or 7 mo after starting treatment for metastatic hormone-sensitive prostate cancer predicts longer survival regardless of the first treatment given with androgen deprivation therapy.
引用
- Parikh M, Tangen C, Hussain MHA, et al. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Eur Urol Oncol. 2024. PMID: 38523017. doi:10.1016/j.euo.2024.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。